ERBB2 and neoplasm: The majority of tumours (76.0%) were sHR positive and simultaneously HER2 negative (hereinafter referred to as sHR positive/HER2 negative), 14,0% were HER2 positive regardless of sHR status, and 10.0% were classified as triple-negative breast cancer (TNBC).